Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,164 | 267 | 90.9% |
| Gift | $335.15 | 7 | 5.9% |
| Education | $180.36 | 20 | 3.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,346 | 66 | $0 (2024) |
| PFIZER INC. | $780.40 | 58 | $0 (2024) |
| Janssen Biotech, Inc. | $714.25 | 46 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $618.53 | 7 | $0 (2022) |
| Braintree Laboratories, Inc. | $471.72 | 25 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $274.02 | 11 | $0 (2022) |
| QOL Medical, LLC | $198.58 | 18 | $0 (2022) |
| Celgene Corporation | $177.54 | 11 | $0 (2024) |
| GENZYME CORPORATION | $136.12 | 7 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $115.63 | 7 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $674.91 | 28 | ABBVIE INC. ($274.97) |
| 2023 | $531.66 | 31 | Janssen Biotech, Inc. ($218.02) |
| 2022 | $1,036 | 44 | ABBVIE INC. ($262.17) |
| 2021 | $367.92 | 15 | AbbVie Inc. ($148.44) |
| 2020 | $340.13 | 11 | Janssen Scientific Affairs, LLC ($105.83) |
| 2019 | $1,384 | 79 | Braintree Laboratories, Inc. ($456.49) |
| 2018 | $860.52 | 49 | AbbVie, Inc. ($306.45) |
| 2017 | $484.31 | 37 | AbbVie, Inc. ($104.19) |
All Payment Transactions
294 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.22 | General |
| Category: Immunology | ||||||
| 12/06/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $15.21 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/19/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $29.42 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $31.91 | General |
| Category: Immunology | ||||||
| 10/01/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: Immunology | ||||||
| 09/17/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $23.52 | General |
| Category: IMMUNOLOGY | ||||||
| 09/06/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.99 | General |
| Category: Immunology | ||||||
| 09/03/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/27/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $26.01 | General |
| Category: IMMUNOLOGY | ||||||
| 08/23/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $26.67 | General |
| Category: Immunology | ||||||
| 08/05/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $19.95 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 07/31/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: Immunology | ||||||
| 07/22/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: Immunology | ||||||
| 07/18/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $26.38 | General |
| Category: IMMUNOLOGY | ||||||
| 07/16/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.65 | General |
| Category: Neuroscience | ||||||
| 06/14/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/10/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: Immunology | ||||||
| 05/22/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $22.59 | General |
| Category: IMMUNOLOGY | ||||||
| 05/14/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.89 | General |
| Category: Neuroscience | ||||||
| 04/23/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $22.55 | General |
| Category: Immunology | ||||||
| 04/16/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.44 | General |
| Category: Neuroscience | ||||||
| 04/11/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $16.42 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 03/23/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ, HUMIRA | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: IMMUNOLOGY | ||||||
| 03/21/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $117.05 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 205 | 206 | $102,269 | $24,628 |
| 2022 | 9 | 435 | 458 | $224,652 | $52,268 |
| 2021 | 10 | 393 | 6,412 | $321,756 | $146,518 |
| 2020 | 8 | 344 | 355 | $156,305 | $38,523 |
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 34 | 34 | $31,620 | $6,939 | 21.9% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 37 | 37 | $21,830 | $6,381 | 29.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 45 | 46 | $8,648 | $4,023 | 46.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 33 | 33 | $22,110 | $3,470 | 15.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 27 | 27 | $14,175 | $1,962 | 13.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 29 | 29 | $3,886 | $1,852 | 47.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 71 | 73 | $67,890 | $14,451 | 21.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 100 | 100 | $67,000 | $9,529 | 14.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 51 | 51 | $30,090 | $9,153 | 30.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 63 | 65 | $11,184 | $4,970 | 44.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 65 | 67 | $8,042 | $3,984 | 49.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 14 | 31 | $6,882 | $3,235 | 47.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 43 | 43 | $22,575 | $3,231 | 14.3% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 12 | 12 | $7,080 | $2,158 | 30.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 16 | 16 | $3,909 | $1,556 | 39.8% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2021 | 11 | 6,000 | $147,000 | $99,653 | 67.8% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2021 | 51 | 51 | $30,090 | $9,340 | 31.0% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 73 | 73 | $48,910 | $9,248 | 18.9% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 35 | 35 | $32,550 | $6,976 | 21.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 55 | 60 | $9,600 | $5,084 | 53.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 77 | 83 | $9,130 | $4,659 | 51.0% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 51 | 52 | $27,300 | $4,351 | 15.9% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 17 | 35 | $7,770 | $3,800 | 48.9% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2021 | 11 | 11 | $6,490 | $2,018 | 31.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 12 | 12 | $2,916 | $1,388 | 47.6% |
About Dr. Robert Fusco, M.D
Dr. Robert Fusco, M.D is a Gastroenterology healthcare provider based in Moon Township, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1881676138.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Fusco, M.D has received a total of $5,680 in payments from pharmaceutical and medical device companies, with $674.91 received in 2024. These payments were reported across 294 transactions from 28 companies. The most common payment nature is "Food and Beverage" ($5,164).
As a Medicare-enrolled provider, Fusco has provided services to 1,377 Medicare beneficiaries, totaling 7,431 services with total Medicare billing of $261,936. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Location Moon Township, PA
- Active Since 11/14/2005
- Last Updated 10/02/2010
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1881676138
Products in Payments
- STELARA (Biological) $1,166
- XELJANZ (Drug) $564.92
- SUPREP BOWEL PREP (Drug) $471.72
- RINVOQ (Biological) $359.56
- ZEPOSIA (Drug) $269.38
- LINZESS (Drug) $254.73
- Humira (Biological) $219.34
- Sucraid (Drug) $172.21
- INFLECTRA (Biological) $164.25
- DUPIXENT (Biological) $162.87
- SKYRIZI (Biological) $145.61
- ENTYVIO (Biological) $140.32
- XIFAXAN (Drug) $129.05
- CREON (Drug) $119.95
- Entyvio (Biological) $117.53
- PANCREAZE (Drug) $106.23
- Creon (Drug) $93.87
- REMICADE (Biological) $92.85
- Trulance (Drug) $92.08
- INJECTAFER (Drug) $85.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Moon Township
Dr. Lester Stine, M.d, M.D
Gastroenterology — Payments: $17,230
Dr. Nicholas Mahoney, M.d, M.D
Gastroenterology — Payments: $12,047
Dr. Richard Kim, M.d, M.D
Gastroenterology — Payments: $10,962
Vincent Pronesti, D.o, D.O
Gastroenterology — Payments: $6,182
James Pilla, D.o, D.O
Gastroenterology — Payments: $1,195